Cytokinetics, Incorporated filings document a specialty cardiovascular biopharmaceutical company with common stock listed on the Nasdaq Global Select Market. Its 8-K reports cover financial results, corporate presentations, MYQORZO® regulatory approvals, clinical and regulatory disclosures, and material capital-structure events such as underwriting agreements for common stock offerings.
Proxy materials describe board elections, executive compensation, auditor ratification and equity plan amendments, including matters tied to the company’s employee stock purchase plan. Other filings address governance changes, risk disclosures, registered securities, exhibits and Inline XBRL cover-page data associated with Cytokinetics’ public-company reporting obligations.
At Cytokinetics, Inc., EVP Research & Development Fady Ibraham Malik exercised 3,500 non-qualified stock options on October 6, 2026, at an exercise price of $7.80 per share, acquiring 3,500 common shares. He sold 3,500 common shares that day at $61.38 per share. The reported transactions were made under a Rule 10b5-1 trading plan.
Cytokinetics, Inc. President & CEO Robert I. Blum exercised 7,500 non-qualified stock options on September 28, 2026, at $10.60 per share, acquiring 7,500 common shares and selling those shares at $65.46 per share the same day. The transactions were reported under a Rule 10b5-1 plan. After the exercise, Blum held 149,245 non-qualified stock options. Separately, the reported holdings include 2,083 shares each held by The Bridget Blum 2003 Irrevocable Trust and The Brittany Blum 2003 Irrevocable Trust; Blum disclaims beneficial ownership of those trust shares.
CYTOKINETICS INC (CYTK) executive Fady Ibraham Malik, EVP Research & Development, reported an option exercise-and-sale transaction in the company’s stock. On September 22, 2026, he exercised a non-qualified stock option for 3,500 shares of common stock at an exercise price of $7.80 per share and acquired the corresponding common shares directly. The filing states that these transactions were made pursuant to a Rule 10b5-1 trading plan. After the option exercise, he held 23,386 shares of common stock directly as reported in the derivative section, and he then sold 3,500 shares of common stock at $68.29 per share on the same date.
CYTOKINETICS INC (CYTK) received a Rule 144 notice covering a proposed sale of common stock beneficially associated with President, CEO and Director Robert I. Blum. The notice relates to up to 97,926 shares of common stock, originally acquired from the issuer as equity compensation between December 2024 and March 2026.
The shares covered are stated to have been sold by the Bridget Blum 2026 Irrevocable Trust, with Robert I. Blum as trustee, and J.P. Morgan Securities LLC acting as agent and attorney-in-fact. The approximate aggregate market value listed for the securities to be sold is $7,094,739, with 139,023,418 shares of this class outstanding and an indicated sale date of September 15, 2026 on NASDAQ.
CYTOKINETICS INC (CYTK) director Robert E. Landry reported selling 1,000 shares of Common Stock on September 15, 2026 in an open market or private transaction at $72.13 per share. After this sale, he directly holds 8,184 shares of CYTK common stock. The filing affirms use of a Rule 10b5-1 trading plan.
CYTOKINETICS INC (CYTK) reported multiple insider transactions by President and CEO Robert I. Blum and related trusts. On September 14, 2026, he exercised options for 7,500 shares of common stock at $10.60 per share under a pre-arranged Rule 10b5-1 trading plan and sold those 7,500 shares at $73.44 per share the same day under the same plan. The filing also reports charitable gifts and transfers totaling over 190,000 shares, including a transfer of 97,926 shares to The Bridget Blum 2026 Irrevocable Trust, where he is co-trustee and disclaims beneficial ownership. On September 15, 2026, that trust sold 97,926 shares at $69.33 per share, with Blum disclaiming any beneficial interest in the shares sold or proceeds.
CYTOKINETICS INC (CYTK) reports that director Robert E. Landry sold 1,000 shares of common stock on September 11, 2026 in a transaction described as a sale in the open market or a private transaction at $74.66 per share. Following this sale, he directly holds 9,184 shares of Cytokinetics common stock. The transaction is affirmed as having been made under a Rule 10b5-1 trading plan, indicating it was executed according to a pre-established arrangement.
CYTOKINETICS, INCORPORATED (CYTK) received a notice that director Robert Landry plans to sell 2,000 shares of common stock under Rule 144 through Morgan Stanley Smith Barney LLC. The planned sale has an indicated aggregate market value of $147,240 as of September 11, 2026.
CYTOKINETICS INC (CYTK) reported that executive vice president of research and development Fady Ibraham Malik exercised options for 3,500 shares of common stock on September 8, 2026 at an exercise price of $7.80 per share and received 3,500 shares of common stock. On the same date, he sold 3,500 shares of common stock at $75.46 per share in a reported sale. Following the option exercise, he held 26,886 derivative option-based shares directly. The company indicates these transactions were carried out under a Rule 10b5-1 trading plan.
CYTOKINETICS INC (CYTK) director Lynne B. Parshall reported selling 5,000 shares of common stock on 2026-09-01 in an open market or private transaction at $71.48 per share. After this sale, Parshall holds 10,784 shares of CYTK common stock directly. The filing affirms the transaction was made under a Rule 10b5-1 trading plan.